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Linear scleroderma (LS) is a localized form of scleroderma characterized by mononuclear cell
infiltration and fibroblast proliferation. In the later stages of the disease, excessive collagen is
deposited with concomitant skin and appendage atrophy. These symptoms suggest a breakdown
of fibroblast cell function, and consequently, growth factors have been thought to play a role in
the pathogenesis of LS. The present study examined the expression of TGF-ß and PDGF in skin
biopsies obtained from patients with LS and from normal subjects. Samples were prepared for
immunohistochemistry. To identify TGF-ß, two polyclonal antibodies were used: TGF-ß1 (RaB4)
and TGF-ß2 (CL-B1/29) and, to identify PDGF, two monoclonal antibodies were used: PDGF-AA
(3E-205) and PDGF-BB (1F-133). Staining for TGF-ß1 and TGF-ß2 was observed around blood
vessels (endothelial cells), and sweat glands in both LS and normal skin. Staining for PDGF-AA
and PDGF-BB was intense in endothelial cells and sweat glands in LS and normal skin.
Mononuclear cell infiltrates and abnormal collagen bundles did not stain for TGF-ß or PDGF.
The strength and extent of staining was evaluated in tissues using a scale from zero (no
staining) to four (strong staining). The amount of  TGF-ß1, TGF-ß2, PDGF-AA and PDGF-BB was
found similar in LS and normal skin. These results do not support the hypothesis that the
excessive fibroblast cell activity and abnormal collagen deposition observed in LS are
associated with downregulation of  TGF-ß  or PDGF.
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Expresión del factor β transformador del crecimiento (TGF-β) y del factor de crecimiento
derivado de las plaquetas (PDFG) en la esclerodermia lineal
La esclerodermia lineal (EL) es una forma localizada de la enfermedad, caracterizada por la
proliferación fibroblástica y los infiltrados linfocitarios perivasculares en la dermis. En los estadios
terminales de la enfermedad, hay depósito de colágeno en exceso con atrofia cutánea y de los
anexos, todo lo cual sugiere una alteración de la regulación de la función fibroblástica, con
participación de los factores de crecimiento en la patogenia de la enfermedad. Este trabajo se
planeó para examinar la expresión de los factores TGF-ß y PDFG en biopsias de piel de
pacientes con EL y de controles sanos, con estudio inmunohistoquímico. Para idenficar el TGF-
ß se emplearon dos anticuerpos policlonales TGF-ß1 (RaB4) y TGF-ß2 (CL-B1/29) y dos
anticuerpos monoclonales para identificar el PDFG: PDFG-AA (3E-205) y PDFG-BB (1F-133).
La tinción para TGF-ß1 y TGF-ß2 se observó alrededor de los vasos sanguíneos pequeños y
de las glándulas sudoríparas tanto en la EL como en la piel normal. La tinción para PDGF-AA
y PDGF-BB fue intensa en las células endoteliales y en las glándulas sudoríparas en la EL y en
la piel normal. El infiltrado linfocitario y los haces colágenos anormales no se tiñeron para TGF-
β ni para PDGF. La intensidad y la extensión de la reactividad evaluada en los tejidos con una
escala de 0 (ausencia de tinción) a 4 (tinción notoria) indican que la expresión de TGF-ß1, TGF-
ß2, PDGF-AA y PDGF-BB son similares en la EL y en la piel normal. Nuestros hallazgos no
apoyan la hipótesis según la cual la actividad fibroblástica excesiva y el depósito de colágeno
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anormal observados en la esclerodermia lineal estén asociados con alteraciones de la
regulación del TGF-ß o del PDGF.
Palabras clave: esclerodermia lineal, factores de crecimiento.
Linear scleroderma (LS) is a distinct form of der-
mal induration confined to an asymmetrical area
of the skin. Althought some clinico-pathological
findings are similar, LS bear minimal relationship
to systemic sclerosis. The lesion may appear
spontaneously but, in most cases, it is preceded
by injury. Early manifestations are difficult to di-
agnose. An ill defined plaque of edema with occa-
sional erythema and pain precedes the typical skin
lesions (1).  Later, the lesions may appear with
distinct features. The plaque ranges from 1 to 15
cm in its largest dimension, are sharply defined
and asymmetrical (2) . The center is smooth and
whitish with various shades of pigmentation. The
surface appears shiny and atrophic.
The lesions are characterized by its cord-like dis-
tribution involving superficial as well as deeper lay-
ers of the skin. The advanced form of the disease
may result in fixation of the skin to underlying struc-
tures. Histological studies have identified that the
initial inflammatory cell infiltrate is replaced by fi-
broblast proliferation and excessive collagen depo-
sition, progressing to fibrosis and kin atrophy (3,4).
Fleischmajer et al. (5,6)  have characterized the
cellular infiltrate of this disease. The histological
sequence of LS is initiated by an inflammatory
cell infiltrate (macrophages and lymphocytes) that
progresses later towards fibroblast proliferation and
collagen synthesis. Thus, it may be that the initial
wave of cellular infiltration by inflammatory cells
sets the stage for the second wave of infiltration
by fibroblasts, which may result in collagen syn-
thesis and fibrous tissue accumulation in the lo-
cal fashion characteristic of LS. The local and pro-
gressive proliferation of fibroblasts and collagen
deposition that correlates with LS progression
suggest an alteration of the control of fibroblast
growth-promoting activities, a process regulated
by growth factors. Transforming growth factor beta
(TGF-ß) and platelet-derived growth factor (PDGF)
are polypeptides widely distributed and critically
involved in cell proliferation and differentiation of
fibroblasts and control of collagen synthesis
necessary for growth, development and repair (7,8).
The present study was designed to examine the
expression of TGF-ß and PDGF in skin biopsies
obtained from patients with LS and from normal
skin obtained from affected patients and from
normal subjects.
Materials and methods
We selected 10 patients from a cohort of 25 pa-
tients with clinical and pathologic diagnosis of LS,
according to the classification of Tufffanely (9)  and
Leroy (3).
After informed consent, skin incisional  biopsies
(1 x 0.5 cm of diameter that included subcutaneous
tissue) were obtained from 10 patients with LS
(affected and normal skin) and from 2 normal
subjects. The normal skin specimens were
obtained from the forearm. The 10 patients have
the subset form of coup du sabre and facial
hemiatrophy. The lesions were well established and
with different time of evolutions: 3 patients with
less than a year; 2 between 1 and 5 years, and 5
patient with 5 or more years of evolution.
Specimens were fixed in formaldehyde, embedded
in paraffin and in 5 µ cross sections.
Antibodies
Two polyclonal antibodies raised in rabbit (Celtrix
Laboratories, Palo Alto, CA) were used recognize
TGF-ß: RaB4 was used to detect intracellular TGF-
ß1, and CL-B1/29, directed against a peptide with
a sequence identical to the amino terminus resi-
dues 1-29 of  TGF-ß2 and detecting intra and ex-
tracellular TGF-ß2. No cross-reaction was de-
tected between these two antibodies. Two mono-
clonal antibodies raised in mouse (Amgen Inc,
Thousand Oaks, CA) were used to recognize
PDGF: clone 3E-205 detecting the AA isoform of
PDGF, and clone 1F-133 detecting the BB isoform
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and with reactivity towards the AB isoform of
PDGF.
Reagents
Phosphate buffered saline (PBS) hydrogen perox-
ide, diaminobenzidine tetrahydrochloride (DAB),
Tween-20 and bovine serum albumin (BSA) were
purchased from Sigma Chemical Co. (St. Louis,
MO). Avidin biotin immunoperoxidase labeling kit
(ABC kit), normal mouse IgG and normal rabbit
IgG were purchased from Vector Laboratories
(Burlingame, CA).
Immunohistochemical analysis for TGF-ß1 and
TGF-ß2. These studies were performed as previ-
ously described (5,10). Briefly, sections were fixed
in cold acetone for 30 min and air dried. Endog-
enous peroxidase was inactivated by 30 minute
incubation in hydrogen peroxide in PBS. Sections
were incubated with 10% normal goat serum (ABC
kit ) in PBS with 0.5% BSA and 0.05% Tween-20
for 45 min. After draining, samples were incubated
with primary antibodies RaB4 and CL-B1/29 and
subsequently diluted 1:40 in PBS at room tem-
perature for 1 h. Samples were rinsed three times
in PBS and incubated with secondary antibody
biotinylated goat anti-rabbit (ABC kit) diluted 1:50
for 30 min. Slides were washed and incubated with
streptavidin peroxidase (ABC kit) diluted in PBS
with 0.5% BSA and 0.05% Tween 20 during 45
min. Samples were exposed to DAB for 2 min,
washed in running water for 5 min, counterstained
with hematoxylin and mounted under coverslips.
Controls were carried out by replacing the primary
antibodies with normal rabbit IgG.
Immunohistochemical analysis
for PDGF-AA and PDGF-BB
After fixation in cold acetone and inactivation of
endogenous peroxidase, samples were incubated
with 10% normal horse serum (ABC kit) in PBS
for 30 min. After draining, samples incubated with
primary antibodies PDGF-AA, 3E-205 and
PDGF.BB 1F-133 diluted 1:200 in PBS for 15 hours
at room temperature. Samples were rinsed three
times in PBS and incubated with secondary anti-
body biotinylated horse anti-mouse IgG (ABC KIN)
for 30 min. After washing, slides were incubated
with streptavidin peroxidase (ABC kit), exposed
to DAB and counterstained with hematoxylin.
Controls were carried out by replacing the primary
antibodies with normal mouse IgG.
Histological analysis
To provide a semi-quantitative comparison of the
expression of these growth factors between LS
lesions and controls, an arbitrary grading scale
from zero to four was used to rate the intensity
and extent of staining in each sample, as previ-
ously described (5). Zero was scored when stain-
ing was absent or very weak; one when the stain-
ing was weak; two when moderate staining was
observed; three, strong staining; and, four  for the
strongest staining observed. Evaluation was per-
formed in a blinded manner by two independent
observers using the same criteria.
Statistics
Results were averaged and expressed as mean ±
standard error of the mean (SEM). Comparisons
were performed by one way analysis of variance
(ANOVA) with Bonferroni‘s correction. Differences
were considered significant when p<0.05.
Results
The clinical characteristics of our patients were
skin involvement consisting of purple, asymmet-
ric and linear indurated plaques. Over half of the
patients had more than one lesion. At the time of
the skin biopsy, the disease had been present a
year or less in three patients, one to five years in
two patients, and more than five years in the re-
maining five patients. Despite the localized nature
of the disease, three patients had severe fibrosis
and atrophy near a major joint that was associ-
ated with significant decrease in the range of mo-
tion of body segment (table 1). Most of the skin
biopsies were obtained from the lower extremities.
By definition, these patients did not have any
manifestations of systemic scleroderma.
Light microscopy confirmed the findings of this
localized form of scleroderma (5,6) (figure 1) with
the inflammatory cellular infiltrate (mononuclear
cells) more obvious around blood vessels and
sweat glands.
The skin obtained from LS lesions displayed in-
tense staining for PDGF-AA and PDGF-BB pre-
dominantly in endothelial cells and sweat glands.
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Mononuclear cell infiltrates and abnormal collagen
bundles were negative for TGF-ß or PDGF. The
strength and extent of staining of TGF-ß1, TGF-
ß2, PDGF-AA and PDGF-BB were similar between
LS lesions and the skin obtained from normal-look-
ing skin from these patients or the two control
subjects (table 2).
TGF-ß1: Staining was intense in LS lesions and
normal skin. The expression of TGF-ß1 and TGF-
ß2 was cytoplasmic, primarily in perivascular
endothelial cells and around sweat glands
(figure 2).
PGDF-AA: Staining was also intense in LS lesions
and normal skin. Staining was observed in perivas-
cular endothelial cells, fibroblasts, keratinocytes
and sweat glands (figure 3 ).
PDGF-BB: staining was weaker but the distribu-
tion was similar to that observed for PDGF-AA (not
shown).
Table 1. Clinical characteristics of patients with linear scleroderma.
Age (years) Gender Appearance  Duration  Localization   Comments
10 F        plaque 5 years leg M, U
20 F        plaque 8 years leg M, U
  9 F        plaque 6 months gluteus I
17 F        plaque 1 years thigh I
24 F        plaque 9 years leg M, U
35 F        plaque 3 years thigh I
28 F        atrophy 10 years thigh I
46 F        plaque 4 years leg M, U
F: female; M: multiple; I: isolated; u, unique.
Table 2. Overall tissue staining and intensity for PDGF-AA,
PDGF-BB, TGF-ß1 and TGF-ß2 in linear scleroderma and
control samples.
 Linear Control Normal t-test
(n=10) (n=10) (n=2)
Scleroderma Skin
PDGF-AA 2.4±0.2 2.3±0.2 2.4±0.2 NS
PDGF-BB 1.8±0.1 1.6±0.1 1.5±0.1 NS
TGF-ß1  2.5±0.3 2.6±0.2 2.4±0.2  NS
TGF-ß2 1.5±0.1 1.6±0.1 1.4±0.1  NS
NS:  not significant
Figure 1. Pathological changes of linear scleroderma are
observed: accumulation of inflammatory cells among collagen
bundles and abnormal collagen deposition. HE, 40X.
As it was noted above, neither PDGF or TGF-ß
staining was associated with mononuclear cell
infiltrates or abnormal collagen bundles in LS le-
sions (figure 4). The specificity of the reactions
was confirmed by the lack of staining in negative
controls incubated with IgG instead of primary
antibody (not shown).
Discussion
The pathogenesis of LS remains undetermined.
Since the disease is characterized by local fibrosis
Figure 2. Staining of TGF-ß1 with RAB antibody in linear
scleroderma. Hematoxylin counterstained, 40X.
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due to collagen deposition, it is assumed that fi-
broblasts may play a key pathogenetic role (3).
Published evidence indicates that among the
cytokines produced by inflammatory cells, and in
particular by macrophages, growth factors play an
important role in regulation of fibroblast function
(11-14). In vitro studies have demonstrated that
fibroblasts incubated with PDGF and TGF-ß ob-
tained from macrophages in culture, exhibit sig-
nificantly more migration (chemotaxis), more pro-
liferation and greater ability to synthesize
collagen than fibroblasts incubated with media
alone (11). Also in in vitro studies it has been shown
that stimulation of the NIH3T3 fibroblast with TGF-
ß resulted in increased expression of the gen pro-
moters for á1 and á2 collagen (12). In addition,
Bolstein et al. (15)  demonstrated that fibroblasts
isolated from skin lesions with scleroderma may
Figure 4. Staining of PDGF-AA with 3E 205 antibody. Patchy
inflammation stains negative for PDGF-AA. Hematoxylin
counterstained, 160X.
Figure 3. Staining of PDGF-AA with 3E 205 antibody in linear
scleroderma. Hematoxylin counterstained, 40X.
be programmed to have increased synthesis of
collagen. Our results are in agreement with those
reported by Gay et al. (16)  who reported expres-
sion of PDGF and TGF-ß in LS lesions, with ex-
pression of PDGF found predominantly in endot-
helial cells lining small capillaries. Taken together,
those studies suggest that the dysfunction of the
fibroblasts seen in LS resulting in excessive rate
of collagen synthesis may be mediated, at least
in part, by increased expression of growth factors.
We designed the present study to examine local-
ization of  TGF-ß and PDGF in human skin ob-
tained from ten patients with linear scleroderma.
These observations were compared with those
made on normal-looking skin samples obtained
from the same patients and from two normal
volunteers. The expression of  TGF-ß and PDGF
of the skin samples obtained from the lesions of
LS was not different than the once seen in the
samples obtained from normal-looking skin
obtained from the same patients or those obtained
from the normal volunteers. In all samples
examined, PDGF and TGF-ß were expressed
primarily in perivascular endothelial cells,
fibroblasts, keratinocytes and around sweat glands
with the same distribution and intensity of observed
in the different samples.
Different interpretations may be given to the lack
of difference in the expression of growth factors
between normal-looking skin and skin affected
with LS. First, it may be suggested that PDGF
and TGF-ß do not play a role in the pathogenesis
of this disease. This argument may be sustained
by the lack of difference in the expression of these
factors in the skin samples with LS, compared
with normal looking skin or skin obtained from
normal subjects. In agreement with this view are
the reports by Needlemann et al. (17), Takehara
et al. (18), Feldman et al. (19), and Gruschwitz et
al. (20) . Needlemann (17) isolated fibroblasts from
skin obtained from patients with systemic sclero-
derma and reported that secretion of TGF-ß by
fibroblasts and the number or receptors TGF-ß in
these cells were not significantly different from
fibroblasts obtained from normal-looking skin  ob-
tained from volunteers. In vitro studies by Takehara
(18) showed fibroblasts obtained from lesions of
patients affected with LS had less proliferation af-
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ter incubation with PDGF or TGF-ß than those
obtained from normal controls. Feldman et al. (19),
and Gruschwitz et al. (20), working independently,
demonstrated that fibroblasts obtained from skin
lesions of patients affected by LS had a similar
mitogenic response after stimulation with PDGF
or TGF- ß. Taken together, these studies may be
interpreted as to suggets that PDGF or TGF-ß do
not play a key role in the pathogenesis of LS.
Second, it also may be argued that the time of the
skin biopsies may have played a decisive role in
the expression of these growth factors. In essence,
the expression of PDGF and TGF-ß may have
been associated with the initial wave of the infil-
trate by immune cells, in particular macrophages
that disappeared by the time of the infiltration by
fibroblasts and the active phase of collagen syn-
thesis. Since these events may precede the clini-
cal manifestations, the predominant infiltration by
immune cells associated with greater synthesis
of cytokines that induce collagen synthesis by fi-
broblasts may have been missed at the time of
the skin biopsy. Although that may have been the
case, the different time of evolution of the clinical
manifestations in our  patients argue against that
contention: three of our patients had clinical mani-
festations of less that a year duration, two patients
had clinical manifestations one to five years dura-
tion, and five patients had clinical manifestations
for five years or longer. Thus, we may argue that
we had access to skin samples with different
stages of the disease and  that in none of those
expression of  PDGF and TGF-ß was significantly
different that in the normal controls.
The role, if any, of these growth factors, an in par-
ticular that of  TGF-ß, may not be dismissed in
the context of the present evidence. In vitro stud-
ies have demonstrated that  TGF-ß stimulate
chemotaxis, proliferation and synthesis of collagen
by fibroblasts. Also, its role in scar formation is
increased by its toxicity to endothelial cells (11)
and it inhibits collagenase synthesis. The latter
characteristics may increase the chances of
replacement of normal-looking tissue by scar tis-
sue. In vitro, it has been demonstrated that PDGF
stimulate chemotaxis and proliferation of fibro-
blasts (11,14,16,21,22). In addition, in vitro stud-
ies have shown that  TGF-ß activates the mouse
a2 (3) and a1 (13) collagen promoters by fibro-
blasts in culture due to its effects on nuclear bind-
ing sites (13). In another study by Kubo et al. TGF-
ß receptor I and II (RI and RII) were up regulated in
dermal fibroblasts in the affected skin of patients
with localizes scleroderma (23). Zheng et al. per-
formed both in vivo studies on the expression of
PDGF ß-receptor protein in scleroderma tissue
and in vitro studies on the expression of PDGF ß-
chain and PDGF ß-receptor mRNA in cultured fi-
broblast derived from both lesions of scleroderma
and normal skin. Immunohistochemistry staining
showed that PDGF ß-receptor expression was
greatly elevated in the dermis of scleroderma le-
sion whereas PDGF ß-receptor were expressed
at low levels in normal skin. Northern blot analy-
sis showed that cultured fibroblast from sclero-
derma had higher expression of PDGF ß-chain
and PDGF ß-receptor mRNA than those from nor-
mal control (24). Taken together, these studies
suggest that PDGF and TGF-ß may play a role in
the pathogenesis of LS. However, noted by Smith
and LeRoy (10,13), the in vitro effects of these
growth factors has not been accompanied by the
same observations in vivo in scleroderma, sug-
gesting that other factors may also play a role in
the pathogenesis of LS.
Kawakami et al. also found that immunoreactivity
with TGF-ß3  tends to increase in the dermal and
subcutaneous fibrosis, fibroblasts and inflamma-
tory cells of patients with solitary morphoea pro-
funda,  however we did not look for that specified
molecule (25).
Finally, it is also possible that PDGF and TGF-ß
play a role in the pathogenesis of LS, but that this
role may not be as important as initially postu-
lated. Observations by Claman (26) and Mican (27)
suggest that cells other than immune cells, and
possibly other mediators, may play a more impor-
tant role in the pathogenesis of LS. In this respect,
mast cells have been described in this disease in
association with endothelial structures and sweat
glands (23). Since one common pathway of the
pathogenesis of LS is the damage of the endothe-
lial cell and capillary obliteration, it is possible that
these events my have been mediated by mast
cells. To the best of our knowledge this postu-
lated has not been either proved  or disproved.
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The end-result of this pathway is local ischemia
and tissue death with subsequent replacement by
fibroblasts and scar all of which are characteristic
of  LS.
The results of this study suggest that increased
expression of these growth factors do not play a
significant role in the pathogenesis of this disease.
However, since we obtained only one sample from
each lesion per patient, our results do not permit
us to rule out definitively a role of these factors in
early stages of the disease, especially in view that
the number of our sample is small.
In summary, our results demonstrate that the ex-
pression and distribution of  TGF-ß and PDGF is
similar in LS lesions and normal skin. TGF-ß and
PDGF may play a role in the pathogenesis of lin-
ear scleroderma at early stages, probably medi-
ating initial fibroblast activation and collagen depo-
sition, followed by subsequent down-regulation of
their expression when the disease is established.
Alternatively, is it possible that these growth fac-
tors do not play any role at all in  the pathogen-
esis of the disease.
These findings do not support the hypothesis that
the excessive fibroblast activity and abnormal col-
lagen deposition observed in linear scleroderma
are dependent on abnormal regulation of  TGF-ß
and/or PDGF.
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